CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
Liora M. Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, Bita Sahaf, Hrishi Srinagesh, Parveen Shiraz, Neha Agarwal, Mark Hamilton, Courtney Erickson, Ashley Jacobs, Jennifer Moon, Christina Baggott, Sally Arai, Sushma Bharadwaj, Laura Johnston, Michaela Liedtke, Robert Lowsky, Everett Meyer, Robert S. Negrin, Andrew R. Rezvani, JUDY A. SHIZURU, Surbhi Sidana, Emily Egeler, Sharon Mavroukakis, Ramya Tunuguntla, Nikolaos Gkitsas-Long, Aidan Retherford, Annie Kathleen Brown, Anne-Louise Gramstrap-Petersen, Raquel Martin Ibañez, Steven A. Feldman, David B. Miklos, Crystal L. Mackall, Kara L. Davis, Matthew J. Frank, Sneha Ramakrishna, Lori Muffly
Topics & Concepts
CD22MedicineImmunologyInternal medicineCancer researchBiologyB cellAntibodyCAR-T cell therapy research